Stock Analysis tagged as

Sector - Healthcare and Social Assistance

  1. 4 Heavily Shorted Stocks That Could Climb Higher

  2. 4 ETFs On Fire Right Now

  3. The War Against Alzheimer's Requires Thinking Small

  4. Neogen Is Almost Cheap

  5. How Intuitive Surgical Justifies Its Lofty Valuation

  6. 2011's Biggest Mergers and Acquisitions

  7. 2011 In Review - Pharmaceuticals

  8. 2011 - Another Sick Year For Larger Med-Tech

  9. 2011 In Review - The Best-Performing ETFs

  10. Hill-Rom: Litigation Equals Opportunity For Investors

  11. Sanofi's Investment Prospects

  12. SonoSite Finds Its Deal

  13. Synovis Has To Bow Out To Get Some Love

  14. Will Qiagen's Restructuring Address The Real Problems?

  15. Renewed Realism May Make Life Tech A Buy

  16. If Pipelines Matter, Novartis Should Be Looking Healthy

  17. Low Risk Stocks With Quality Upside

  18. Medtronic May Be A Heavyweight, But It Can Still Hit Hard

  19. Medtronic Stable In A Challenging Market

  20. If The Economy Holds, Agilent Is A Buy

  21. Covidien Delivers Once Again

  22. Meridian Biosciences – Stealth Income Play

  23. Is Hologic A Coiled Spring?

  24. If CareFusion Can Execute, This Is A Major Bargain

  25. Pretty Up Your Portfolio

  26. Becton Dickinson Moves The Bar Lower

  27. CVS Shows Its Resilience In Any Economy

  28. Should Pfizer Forget R&D Altogether?

  29. Big Values In Big Pharma

  30. Biogen Idec Has Built A Valuable Franchise

  31. No Rattle At HUM

  32. Merck's Penance Has Gone On Long Enough

  33. Zimmer Looking To Escape Its Value Trap

  34. VCA Antech Cut Down To Value

  35. Bizarre Baxter Struggle To Grow

  36. Abbott Has Benefited From Its Diversification

  37. Stryker Scraping By

  38. Abbott Labs Joins The Separation Movement

  39. St. Jude Still A Patient Trade

  40. High Yielding Equities

  41. Can AngioDynamics Get Hearts Racing?

  42. 3 Reasons To Own Lincare Holdings

  43. PPD Goes Private

  44. The 3 Highest Yielding Pharma Stocks

  45. MELA Gets A Surprising "Yes"

  46. Vivus Tries A New Path

  47. Endo And Forest – Dumpster-Diving In Pharma

  48. R&D The Future For Life Sciences Equipment Firms

  49. When Times Are Tough, Should Investors Go Swiss?

  50. PerkinElmer Adds High-End Tools To Its Box

  51. Bio-Reference Labs Posting Impressive Internal Growth

  52. Medtronic's Healthy Growth Outlook

  53. Are Buybacks A Bad Sign?

  54. Seattle Genetics – And Now The Hard Bit

  55. Betting On Healthcare's Growth Engine

  56. Why Insiders Are Buying This Biotech Stock

  57. Dendreon's Bull Story In Intensive Care

  58. CVS Still Needs to Prove Itself

  59. BD Healthy, But No Great Bargain

  60. Hologic Holding Its Place

  61. The Perpetual Boston Scientific Turnaround Story

  62. Illumina Gets Capped And Cut

  63. Teva And Mylan Show Some Value Remains In Generics

  64. Covidien's Image Starting To Change

  65. Top Dividend Stocks Owned By The Pros

  66. Bard Not So Bulletproof

  67. LabCorp Battling Flat Free Cash Flows

  68. Four Drug Stocks To Watch On Thursday

  69. St. Jude's Healthy Prognosis

  70. Top Healthcare Dividend Stocks

  71. Stryker's Diversification Paying Off

  72. Should Investors Circle Back To Cubist?

  73. Huge Dividends You Can Bank On

  74. Three Safe Sectors For The Summer

  75. Should Biotech Investors Go Where Institutions Won't?

  76. Affymetrix's Downward Spiral Continues

  77. Getting Drugged On Growth

  78. The Best IPOs From The First Half

  79. Immucor Passes Its Last Test

  80. Top Drug Stocks

  81. Investing For Growth And Value

  82. Drugstores Are A Healthy Bet

  83. Siemens Says The Easy Work Is Done

  84. Pleasure And Pain For Pfizer

  85. More To Merck Than Meets The Eye?

  86. Johnson & Johnson Surrenders In Stents

  87. Will A Shake Up Cure AngioDynamics' Malaise?

  88. Lipitor: Pfizer's Loss Is Watson's Gain

  89. Should Investors Worry If Gen-Probe Doesn't Sell Out?

  90. 3 Reasons To Own Moog Inc.

  91. A Dull ASCO And The Usual Sell-Off

  92. Arena's New Data Doesn't Change Obesity Pill Outlook

  93. Medtronic Still Muddling Through

  94. Will Nestle Succeed Where Others Have Failed?

  95. Mergers In Orthopedics Could Heat Up Stocks

  96. Agilent Overshoots

  97. Clorox Ready For A Breather

  98. With Mylan, Maybe Smaller Is Better

  99. Teva And Cephalon Solve Each Other's Problems

  100. 7 Dividend Stocks With Big Payouts

Investopedia Features
  1. Choosing Quality Mutual Funds

    Our step-by-step mutual fund scoring system will help you uncover the top-quality funds.
  2. Guide to Stock Picking Strategies

    Learn about the most popular stock-picking strategies, including their philosophies, methods, and tools.
  3. Advanced Financial Statement Analysis

    Learn what it means to do your homework before investing in a company.
  4. World's Greatest Investors

    Here you can read about the backgrounds and achievements of those people who have mastered the art of investing.
  5. The Industry Handbook

    Take a look at the various techniques to determine the value and quality of companies from an industry perspective.
Trading Center